4//SEC Filing
Blue Horizon Enterprise Ltd 4
Accession 0001062993-25-011153
CIK 0001623526other
Filed
Jun 5, 8:00 PM ET
Accepted
Jun 6, 4:20 PM ET
Size
10.8 KB
Accession
0001062993-25-011153
Insider Transaction Report
Form 4
Skorpios Trust
10% Owner
Transactions
- Sale
Common Stock
2025-06-04$10.20/sh−3,000,000$30,600,000→ 3,906,181 total(indirect: See Footnote)
Blue Horizon Enterprise Ltd
10% Owner
Transactions
- Sale
Common Stock
2025-06-04$10.20/sh−3,000,000$30,600,000→ 3,906,181 total(indirect: See Footnote)
Ezbon International Ltd
10% Owner
Transactions
- Sale
Common Stock
2025-06-04$10.20/sh−3,000,000$30,600,000→ 3,906,181 total(indirect: See Footnote)
Montrago Trustees Ltd
10% Owner
Transactions
- Sale
Common Stock
2025-06-04$10.20/sh−3,000,000$30,600,000→ 3,906,181 total(indirect: See Footnote)
Footnotes (1)
- [F1]Blue Horizon Enterprise Ltd. ("Blue Horizon") is the direct owner of 2,967,621 shares of the issuer's common stock and Ezbon International Limited ("Ezbon") is the direct owner of 938,560 shares of the issuer's common stock. Skorpios Trust ("Skorpios") is the sole owner of each of Blue Horizon and Ezbon. Montrago Trustees Limited ("Montrago Trustees") is the corporate trustee of Skorpios Trust. Each of Blue Horizon and Ezbon disclaim beneficial ownership of the shares of the issuer's common stock held by the other, and each of Skorpios Trust and Montrago Trustees disclaim beneficial ownership of the issuer's securities except to the extent of their pecuniary interest therein.
Issuer
Stoke Therapeutics, Inc.
CIK 0001623526
Entity typeother
IncorporatedVirgin Islands, British
Related Parties
1- filerCIK 0001869057
Filing Metadata
- Form type
- 4
- Filed
- Jun 5, 8:00 PM ET
- Accepted
- Jun 6, 4:20 PM ET
- Size
- 10.8 KB